Keros Therapeutics director Prener sells 575 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Keros Therapeutics, Inc. director Anne Prener reported two direct common-stock sales totaling 575 shares on November 17, 2026: 433 shares at a $10.77 weighted average price, with transaction prices ranging from $10.02 to $10.98, and 142 shares at an $11.03 weighted average price, with prices ranging from $11.03 to $11.04. Both sales were made under a Rule 10b5-1 trading plan adopted August 6, 2026.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 433 | $10.77 | $5K |
| Sale | Common Stock F1, F3 | 142 | $11.03 | $2K |
Footnotes (3)
- F1. The transaction was pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 6, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.02 to $10.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.03 to $11.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Were Anne Prener's KROS sales made under a Rule 10b5-1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.